BUY Lupin LimitedAmbareesh Baliga

byAmbareesh BaligaHorizon: NA (inferred 1–3 months)28 Aug 2026via ET Now (Live)

Entry₹2,171.5Inferred
Target₹2,400
Total upside +10.52%
Stop lossNot given
CMP₹2,1054h ago
Active-3.06%+14.01%upside left 3 mo left

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Sept, 8:50 pm IST
23 supporting1 neutral3 opposing
Supports the BUY call (23)

MACD above its signal line — bullish momentum

Technicals · macd·7 Sept · today

RSI at 20 — oversold territory

Technicals · rsi·7 Sept · today

Lupin receives US FDA approval for Modafinil 100 mg, 200 mg tablets

NewsCnbc-Tv18·4 Sept · 3d ago

(opens in new tab)

Lupin Ltd has received approval from the U.S. FDA for its Modafinil Tablets, USP.

BSE · Company Update·4 Sept · 3d ago

(opens in new tab)

9 advisors have active long-term BUY calls on this stock, with 3 issued in the last 14 days

Advisor consensus · adjacent horizon·27 Aug · 2w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.